01/31/23 7:00 AMNasdaq : AVXL earningshigh shortAnavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment ofRHEA-AIneutral
12/14/22 7:00 AMNasdaq : AVXL managementclinical trialhigh shortAnavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s TrialAnavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’sRHEA-AIneutral
12/12/22 7:00 AMNasdaq : AVXL conferenceshigh shortAnavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceAnavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’sRHEA-AIneutral
12/02/22 4:30 PMNasdaq : AVXL high shortAnavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment ofRHEA-AIneutral
12/01/22 8:26 PMNasdaq : AVXL clinical trialhigh shortANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s DiseaseRobust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results Plan to Meet with Regulatory Authorities to Determine Next Steps NEWRHEA-AIneutral
11/28/22 7:00 AMNasdaq : AVXL earningshigh shortAnavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business UpdateAnavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative andRHEA-AIneutral
11/23/22 7:00 AMNasdaq : AVXL earningshigh shortAnavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment ofRHEA-AIneutral
11/08/22 7:00 AMNasdaq : AVXL conferenceshigh shortAnavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’sRHEA-AIneutral
11/07/22 7:00 AMNasdaq : AVXL high shortAnavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X SyndromeAnavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’sRHEA-AIvery positive
10/17/22 7:00 AMNasdaq : AVXL clinical trialhigh shortAnavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’sRHEA-AIneutral